Baird Maintains Outperform on Axsome Therapeutics, Raises Price Target to $246

Benzinga Newsdesk www.benzinga.com Positive 89.2%

Neg 0% Neu 0% Pos 89.2%

Baird analyst Joel Beatty maintains Axsome Therapeutics (NASDAQ:AXSM) with a Outperform and raises the price target from $241 to $246.